CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
- 1 January 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (1), 48-58
- https://doi.org/10.1158/1535-7163.mct-07-0042
Abstract
Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma. The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML. We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells. In KBM5 and K562 cells, imatinib, INNO-406, or IFN-α increased CXCR4 expression and migration. This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-α. Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system. MSC coculture protected KBM-5 cells from imatinib-induced cell death. These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267. Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells. [Mol Cancer Ther 2008;7(1):48–58]Keywords
This publication has 44 references indexed in Scilit:
- Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cellsSurgery, 2007
- CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironmentBlood, 2006
- NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemiaBlood, 2005
- Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancerMolecular Cancer Therapeutics, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences of the United States of America, 2005
- Cytokine Expansion Culture of Cord Blood CD34 + Cells Induces Marked and Sustained Changes in Adhesion Receptor and CXCR4 ExpressionsThe International Journal of Cell Cloning, 2003
- Integrins: Bidirectional, Allosteric Signaling MachinesCell, 2002
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- The α-Chemokine, Stromal Cell-derived Factor-1α, Binds to the Transmembrane G-protein-coupled CXCR-4 Receptor and Activates Multiple Signal Transduction PathwaysJournal of Biological Chemistry, 1998